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Abstract 
Prepro-vasoactive intestinal peptide @reproVIP) was expressed in NIH 3T3 cells, and the preproVIP-derived peptides produced by the cells were 
analyzed by chromatography combined with sequence-specific radio-immunoanalysis. In accordance with what has previously been reported on 
processing in non-endocrine cell lines, the VIP precursor was processed poorly in these non-endocrine cells. Mainly an extended form of VIP could 
be detected in the media from the cells, and no immunoreactivity specific for amidated VIP was found. However, by changing the dibasic cleavage 
site positioned N-terminal to the VIP sequence in the precursor into the consensus equence (Arg,X,Lys/Arg,Arg) for the ubiquitous processing 
enzyme furin, thought to process, e.g. insulin receptors, factor VII, and by deleting residues 156170 in the VIP precursor, expression of amidated 
VIP was obtained in this fibroblast cell line. Peptides from the wild-type VIP precursor as well as peptides from the mutated VIP precursor were 
found to be able to stimulate the adenylate cyclase in cells expressing the VIP receptor. 
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1. Introduction 
Vasoactive intestinal polypeptide (VIP) is a 28 amino 
sacid neuropeptide with a broad range of biological ac- 
tivities. The precursor for VIP (preproVIP) is synthe- 
sized as a 170 amino acid polypeptide, which after re- 
moval of the signal peptide is proteolytically processed 
at mono and dibasic cleavage sites into a N-terminal 
flanking peptide (preproVIP 22-79), PHM (peptide with 
N-terminal His and C-terminal Met-amide), preproVIP 
111-122, VIP, and a C-terminal flanking peptide (pre- 
proVIP 1% 170), as shown in Fig. 1. The dibasic amino 
acids C- terminal to the VIP and PHM sequences are 
removed with a carboxypeptidase H-like activity and the 
C-terminal glycine residue in PHM and VIP is converted 
by peptidyl-glycine a-amidating monooxygenase (PAM) 
to amidated PHM and VIP. In some instances the dibasic 
cleavage site C-terminal to PHM is left uncleaved result- 
ing in a C-terminal extension of PHM to a 42 amino acid 
peptide, PHV (peptide with N-terminal His and C-termi- 
nal Val) (Fig. 1). The ratio of PHM to PHV is 1:l in 
gastric antrnm and 9: 1 in colon and brain, and thus this 
alternative processing is tissue specific. [ 1,2]. In the pres- 
ent paper, we report the expression of cDNA encoding 
preproVIP in a non-endocrine cell line, NIH 3T3. These 
cells lack secretory granules, and, as expected, the pre- 
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cursor was poorly processed. In an attempt to obtain 
efficient processing of the cleavage site positioned N- 
terminal to the VIP sequence in the precursor, the resi- 
dues at position 121 and 122 were both changed into 
Arg, resulting in a tetrabasic cleavage site. This corre- 
sponds to the consensus cleavage site (Arg,X,Lys/ 
Arg,Arg) for the ubiquitous processing enzyme furin, 
which processes a number proproteins e.g. the insulin 
receptor, factor VII and factor IX [3-51. Previously it was 
reported that when a C-terminal truncated NPY (NPY- 
Gly,Lys,Arg) is expressed in non-endocrine cells, the 
cells synthesize amidated NPY [6]. In order to probe the 
possibility of expressing amidated VIP in NIH 3T3 cells, 
a truncated VIP precursor with residues 15&l 70 deleted 
was constructed. This truncation was made on the tetra- 
basic VIP mutant precursor resulting in a VIP precursor 
with a tetrabasic cleavage site N-terminal to the VIP 
sequence and with only Gly,Lys,Arg as the C-terminal 
extension of VIP. With this mutant it was possible to 
obtain expression of amidated VIP in the NIH 3T3 cell 
line, indicating that non-endocrine cell lines might be a 
promising alternative to chemical synthesis for produc- 
tion of amidated or otherwise modified peptide 
hormones and neuropeptides. 
2. Experimental 
2.1. DNA construction 
The VIP cDNA, (kindly provided by Professor H. Okamoto, Tohuko 
University School of Medicine, Sendai 980, Japan), lacked the se- 
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quences encoding the precursor signal sequence. In order to obtain a 
full-length VIP cDNA the missing part was obtained by PCR on human 
genomic DNA. After verification of the PCR fragment by sequence 
analysis, the fragment was subcloned into the VIP cDNA resulting in 
a full length cDNA. The 5’ PCR primer introduced at the same time 
a BamHI restriction enzyme site 5’ to the initiation codon. 
To obtain expression of the VIP cDNA in mammalian cells, an 
expression vector containing the human growth hormone polyadenyla- 
tion signal and a human ubiquitin promoter was constructed in the 
following way: the promoter from the human ubiquitin C gene [7] was 
subcloned as a Hind111 fragment into HindIII-digested pUC19 resulting 
in pHD183. A Klenow-treated SmaI-EcoRI fragment from pHD184 
[8] containing the human growth hormone polyadenylation signal was 
subcloned into a blunt-ended EcoRI-digested pHD183. This resulted 
in the expression vector pBW87. A 1,130 bp BamHI-DraI VIP cDNA 
fragment was rendered blunt by Klenow polymerase and subcloned 
into blunt-ended BamHI-digested pBW87 resulting in the preproVIP 
expression vector pBW91. By using the DruI restriction enzyme site 
in the VIP cDNA, the CC tailing which arose from the original 
cloning of the VIP cDNA [9] was excluded. The two mutants: 
[PV121,122RR]preproVIP (tetrabasic mutant) and [PV121,122RR, 
d156170lpreproVIP (tetrabasic, 15&170-deletion mutant) were intro- 
duced by site-directed mutagenesis by the Altered sites in vitro mut- 
agenesis ystem (Promega, Wisconsin, USA) and the mutagenic primers 
5’-AGT GAC GTT TGC GAC GTA CAG GGT CT-3’ for the intro- 
duction of arginine in residues 121 and 122, and 5’-TCT TIT TCA 
TCA CCT CTT TCC ATT-3’ for deletion of residues 156170. 
The deletion was performed on the cDNA encoding the mutant 
[PV121,122RR]preproVIP, thereby resulting in a double mutant. The 
introduced mutations were verified by sequence analysis. The mutated 
cDNAs were subcloned as XbaI-EcoRI fragments into XbaI-EcoRI- 
digested pBW91 resulting in pBW125 encoding PV121,122RR]prepro- 
VIP and pBW135 encoding [PV121,122RR;d15617O]preproVIP. 
2.2. Cell culture and transfection 
NIH 3T3 cells from ATCC (MD, USA) were grown at 10% CO2 in 
Dulbecco’s modified Eagles medium supplemented with 10% newborn 
calf serum (NCS), 50 IU penicillin and 5O&ml streptomycin. The cells 
were transfected with 20 fig of the peptide expression vector and 
cotransfected with 2 pg of pSV2neo using the calcium phosphate pre- 
cipitate procedure HO]. Stable clones were selected in NIH 3T3 medium 
supplemented with 0.6 mg/ml G418 (Sigma). 
24 h cell culture media were collected from a confluent 100 mm Petri 
dish receiving fresh cell culture media containing only 0.5% newborn 
calf serum 24 h before harvest. 
2.3. Radioimmunoassays 
Four different antisera recognizing different peptides in the VIP 
precursor were used: antiserum Ab 5598 (the general VIP antiserum) 
recognizing an internal region of VIP and reacting with both C- and 
N-terminal extended VIP forms; antiserum Ab 5603 which is specific 
for the amidated C-terminus of VIP, as it does not react with glycine- 
extended VIP or VIP with a carboxy group at the C-terminus [ 11,121; 
antiserum Ab 73 14 recognizing preproVIP 156170; and antiserum Ab 
3668 recognizing both PHM and PHV [l] (see also Fig. 1 for the 
recognition sites of the antisera). 
2.4. Chromatography - _ 
2.4.1. Gelfiltration. 24 h cell culture media from stable clones were 
aonlied to a Seohadex G 50 Sunerline column (11 x 1,000 mm), as 
described [13]. The columns were calibrated with synthetic VIP and 
preproVIP 156 170. The fractions were freeze-dried and reconstituted 
in assay buffer prior to radioimmunoassay. DB 2000 and vitamin B,, 
were used as void volume marker and total volume marker, respec- 
tively. 
2.4.2. HPLC. The peak fractions of VIP immunoreactive material 
in the gel filtration profiles of media from NIH- 9-l-E4 or NIH-20-2- 
E2. were uooled (fractions 51-57 and 52-60 from the gel filtrations of 
NIH-9-l-B4 and ‘NIH-20-2-E2, respectively). The pools were freeze- 
dried and reconstituted in H,O with 0.1% TFA and analyzed by HPLC 
as described previously [l]. The media from clone NIH-23-3-Cl were 
applied directly to the column. Gradient elution was done at 30°C with 
99% ethanol (Lichrosolv, Merck, Germany) containing 0.1% TFA (sol- 
vent B). The elution gradient was isocratically 10% for 2 min, l&25% 
solvent B for 4 min, 25-70% for 50 min, 70-80% for 4 min and isocrati- 
tally for 10 min. The flow rate was 0.5 ml/min, and fractions of 0.5 ml 
were collected, freeze-dried in a speed vacuum concentrator, econsti- 
tuted in assay buffer and analyzed by radioimmunoassay. The column 
was calibrated in separate runs with synthetic VIP and preproVIP 
156170. 
2.4.3. cAMPassay. For CAMP assays a stable CHO clone, CHO-60- 
l-A6 expressing the rat VIP receptor was used (the rat VIP receptor 
cDNA was kindly provided by Prof. Nagata, Osaka Bioscience Insti- 
tute, Osaka, Japan). 10’ cells/well were seeded in 24-well cell culture 
dishes, and the following day the cells were washed twice in fresh NIH 
3T3 cell culture media containing only 0.5% NCS, stimulated with 0.5, 
5 or 50 ~1 24-h media from either NIH 3T3, NIH-9-l-E4 or NIH-23- 
3,Cl cells in the presence of 0.1 mM I-methyl-3-isobutylxanthine. The 
cells were stimulated in 0.5 ml NIH 3T3 cell culture media containing 
0.5% NCS for 45 min at 37°C. After the incubation the cells were 
washed twice in Kreb’s-Ringer- HEPES buffer, pH 7.4, containing 2.5 
mM CaCl,, 1 mM MgCl,, 0.1 g bovine serum albumin/100 ml, 1% 
Bacitracin and 1 mM /I-mercaptoethanol. CAMP was extracted by 
incubating the cells for 20 rnin on ice in 100 ~1 0.4% perchloric acid. 
After centrifugation, CAMP in the supematant was quantified using a 
CAMP radioimmunoassay kit from Amersham (UK). 
3. Results 
Stable NIH 3T3 clones expressing preproVIP, 
[PV121,122RR]preproVIP and [PV121,122RRJl56- 
170lpreproVIP were established, and the preproVIP de- 
rived peptides found in the media were characterized by 
gel filtration combined with radioimmunoassays specific 
for preproVIP 156-170 (Ab 7314), and VIP (Ab 5598). 
Fractions from gel filtrations of the [PV 12 1,122RRJ 156 
170lpreproVIP clones were also analyzed with the amide 
specific VIP antiserum (Ab 5603). In addition, the VIP 
immunoreactive material was characterized by HPLC 
combined with radioimmunoassay. For each construct, 
the gel filtrations were performed on 2-3 different clones, 
and the HPLC characterizations on at least two different 
clones. 
3.1. Processing of prepro VIP in NIH 3 T3 cells 
Fig. 2 (upper panel) shows a gel filtration profile of the 
peptides found in the media from a stable clone express- 
ing preproVIP (NIH-9- 1 -E4). In the preproVIP 156170 
profile, a part of the immunoreactive material eluted as 
the synthetic standard. The VIP immunoreactivity was 
eluting earlier than the standard, indicating that VIP is 
extended, probably at the C-terminus as this peak also 
reacted with the radioimmunoassay detecting preproVIP 
156170. 
To further characterize the VIP immunoreactive mate- 
rial eluting from the gel filtration column, the peak frac- 
tions were pooled (peak I, fractions 51-57, Kd 0.36 
0.52) and analyzed by HPLC (Fig. 2, lower panel). The 
material eluted as a single peak reacting both with the 
VIP and the preproVIP 156170-specific antisera, indi- 
cating that this peak consists of C-terminally extended 
VIP. No immunoreactive material for PHM or PHV (Ab 
3668) could be detected (data not shown). 
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Fig. 1. Schematic representation of preproVIP and the preproVIP derived peptides. The recognition sites of the antisera used are indicated. 
3.2. Processing of [PVl21,122RR]prepro VIP in NZH 
3T3 cells 
The gel filtration profile of a stable clone expressing 
[PV121,122RR]preproVIP is shown in Fig. 3 (upper 
panel). The VIP immunoreactive material eluted as one 
major peak at the same position as the wild-type peak 
(Fig. 2). However, with the mutant no earlier eluting VIP 
immunoreactivity was found, indicating that the intro- 
duced tetrabasic leavage site was completely cleaved. As 
for the wild-type, a part of the preproVIP 156170 im- 
munoreactive material eluted as the standard. The peak 
(fractions 52-60, Kd 0.34-0.49) reacting with both VIP 
(Ab 5598) and preproVIP 156-l 70-specific antisera were 
pooled and characterized by HPLC (Fig. 3, lower panel). 
The elution profiles were similar to the HPLC profiles 
from the wild-type preproVIP (Fig. 2, lower panel). 
3.3. Processing of[PVl21,122RR,Al56-170]preproVZP 
in NZH 3T3 cells 
In the gel filtration profiles from clones expressing this 
mutant, VIP immunoreactive material eluted as the syn- 
thetic standard. (Fig. 4, upper panel). Some of this mate- 
rial also reacted with the amide-specific VIP antiserum, 
demonstrating that a fraction of the VIP immunoreactive 
material was amidated. As expected no preproVIP 156 
170 immunoreactivity was found (data not shown). 
To further characterize the VIP immunoreactivity 
found in the media, the media were applied to HPLC, 
and the fractions were analyzed with the two VIP anti- 
sera, Ab 5598 and Ab 5603 (Fig. 4, lower panel). The Ab 
5598 immunoreactive material consisted of two peaks, 
one co-eluting with the standard and also reacting with 
the antiserum specific for amidated VIP, and a peak 
eluting as a more hydrophilic peptide reacting only with 
the Ab 5598 antiserum. This peak probably consists of 
VIP C-terminally extended with the residues Gly-Lys- 
Arg. 
3.4. Biological activity of the expressed peptides 
The biological activity of the VIP immunoreactive ma- 
terial produced by a clone expressing preproVIP (NIH- 
9- 1 -E4) and by a clone expressing [pV12 1,122RRJ 156 
17OlpreproVIP (NIH-23-3-Cl) was studied. The concen- 
trations of immunoreactive material (both Ab 5598 and 
Ab 5603) in the media from control cells, NIH-23-3,Cl 
cells and NIH-9-l-E4 cells are shown in Table 1. The 
control cells expressed no detectable amounts of either 
Ab 5598 or Ab 5603 immunoreactivity. The two clones 
produced comparable concentrations of Ab 5598 im- 
munoreactive material (3.6 nM vs. 4.3 nM), whereas the 
media from NIH-23-3,Cl cells contained approximately 
a lOO-fold higher amount of Ab 5603 immunoreactivity 
(specific for amidated VIP) than the NIH-9-l-E4 cells 
(2.7 nM vs. 23 PM). 
Addition of 0.5 ~1 and 5 ,~l control media to CHO-60- 
1 -A6 cells gave no measurable production of CAMP, and 
addition of 50 ~1 control media resulted 1.4 pmol CAMP/ 
lo5 cells (Table 2). In contrast addition of 50 ,~l media 
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Fig. 2. (Upper panel) Gel filtration profiles of VIP (Ab 5598, l ) and 
preproVIP IS-170 (Ab 7314, Cl) immunoreativities in culture medium 
from cells stably expressing preproVIP. (Lower panel) HPLC analysis 
of the immunoreative VIP peak in the gel filtrations (fractions pooled 
are indicated by open rectangle in upper panel). The fractions were 
analyzed for VIP (Ab 5598) and preproVIP 156170 (Ab 7314) im- 
munoreactivities. (symbols as above). The elution positions of VIP and 
preproVIP 156-170 are indicated by open and closed arrows, respec- 
tively. 
from both clones to the CHO-60-l-A6 cells resulted in 
a significant increase in CAMP (Table Z), and also 5 ~1 
media from the two clones were able to increase the 
CAMP production in CHO-60-1 -A6 cells. 
4. Discussion 
When preproVIP is expressed in NIH 3T3 cells, very 
low amounts of amidated VIP (Table 1) are found in the 
cell culture media. This demonstrates, as also found for 
other peptide precursors expressed in fibroblast cell lines 
[ 14-161 that these cell lines have no or only limited proc- 
essing capacity. Nevertheless, when the VIP im- 
munoreactive material is characterized by gel filtration, 
one major peak is found. This peak also reacts with the 
preproVIP 1X-170 antiserum but not with the PHMl 
PHV antisera, indicating that the dibasic processing site 
N-terminal to the VIP sequence is susceptible to some 
kind of cleavage. 
In an attempt to obtain expression of amidated VIP 
in NIH 3T3 cells two preproVIP mutants were ex- 
pressed: (i) [PVl2 l,l22RR]preproVIP, where the dibasic 
cleavage site N-te~inal to the VIP sequence was 
changed into a tetrabasic cleavage site (Arg”‘, 
gel filtration 
h 
0.0 0.2 0.4 0.6 0.8 1.0 
Kd 
6ooc HPLC 
0 
0 20 40 60 80 
Fraction number 
Fig. 3. (Upper panel) Gel filtration profiles of VIP (Ab 5598, e) and 
preproVIP 156170 (Ab 7314, 0) immunoreativities in cell culture 
medium from cells stably expressing [pV12 1,l ZZRR]preproVIP. 
(Lower panel) HPLC analysis of the i~unoreactive VIP peak in the 
gel filtrations (fractions pooled are indicated by a rectangle in upper 
panel). The fractions were analyzed for VIP (Ab 5598) and preproVIP 
156170 (Ab 7314) immunoreactivities. The elution positions of VIP 
and preproVIP 156-170 are indicated by open and closed arrows, 
respectively. 
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Fig. 4. (Upper panel) Gel filtration profiles of VIP (Ab 5598, 0) and 
amide specific VIP (Ab 5603,O) immunoreactivities in the cell culture 
media from cells stably expressing [PV121,122RRJl56-170]prepro- 
VIP. (Lower panel) HPLC analysis of VIP (Ab 5598) and amide-spe- 
cific VIP (Ab 5603) immunoreactivities in the cell culture media. 
Arg122,Lys123,Arg1ti), which fits the consensus sequence 
Arg,X,Lys/Arg,Arg for cleavage by the ubiquitous 
enzyme furin [17]; (ii) [PV121,122RRJ156170]- 
preproVIP, a double mutant containing the tetrabasic 
sequence and with residues 156170 deleted. 
Table 1 
VIP immunoreactive material in NIH 3T3, NIH-9-l-E4 and NIH-23- 
?-Cl as determined by the general (Ab 5598) and the amide-specific VIP 
antisera 
Media from AB 5598 (PM) Ab 5603 (OM) 
NIH 3T3 
NIH-9-1, E4 
NIH-23-3, Cl 
< std* 
4,337 
3,550 
< std* 
23 
2,650 
*Below detection limit. 
Table 2 
Induction of CAMP production by media from NIH 3T3, NIH-9-l-E4 
and NIH-23-3-Cl cells 
Media added 
from 
CAMP @M/lOS CAMP (pM/lO’ CAMP @M/10’ 
cells) produced cells) produced cells) produced 
after addition after addition after addition 
of 0.5 ~1 media of 5.0 ~1 media of 50 ~1 media 
(n = 4) (n = 4) (n = 4) 
mean f S.E.M. mean f S.E.M. mean f S.E.M. 
NIH 3T3 < std < std 1.4 * 0.3 
NIH-9-1, E4 1.0 f 0.1 5.2 f 2.6 23.5 f 0.5 
NIH-23-3, Cl 1.1 f 0.2 12.6 f 3.3 36.5 k 3.4 
The amount of CAMP produced after addition of, respectively 0.5, 5 
or 50 ~1 media from the three cell lines to cell culture wells containing 
CHO-60- 1 -A6 cells in 500 ~1 media was measured (< std, below detec- 
tion limit. 
The expression of [PV121,122RR]preproVIP in NIH 
3T3 cells resulted in efficient cleavage at the cleavage site 
N-terminal to VIP (Fig. 3 upper panel), but still no VIP 
immunoreactive material eluting as the synthetic stand- 
ard on gel filtration was found. The major part of the 
VIP immunoreactive material from cells expressing 
[PV121,122RR,d156-170lpreproVIP eluted as the syn- 
thetic standard on gel filtrations, and part of the im- 
munoreactivity also reacted with the amide-specific VIP 
antiserum (Fig. 4). HPLC analysis of the media showed 
that the amide-specific immunoreactive material eluted 
as the synthetic VIP standard. Consequently this cell line 
contains both carboxypeptidase H-like activity and ami- 
dation enzyme. The expression of the amidation enzyme 
mRNA in NIH 3T3 cells has previously been shown [ 181. 
Although amidated VIP is expressed, the processing is 
incomplete and the major part of the VIP immunoreac- 
tivity detected with Ab 5598 elutes from the HPLC col- 
umn as a more hydrophilic peptide. This indicates that 
the peptide exists in an extended form, probably C-termi- 
nally extended with Gly-Lys-Arg. 
Nevertheless, we have shown that by introducing the 
appropriate mutations in the peptide precursor, it is pos- 
sible to synthesize amidated VIP in a non-endocrine cell 
line. 
A minimum length of about 65 amino acids is required 
for entering the secretory pathway [19,20], and for pro- 
duction of small amidated or otherwise modified pep- 
tides in non-endocrine cells, a C- or N-terminal extension 
of the peptides are necessary. As also showed for the 
protein C precursor [21], we found that it is possible to 
alter the dibasic cleavage site in the VIP precursor in 
such a way that the resulting precursor is efficiently 
cleaved in non-endocrine cells. The same was found 
when a tetrabasic mutant of human insulin was ex- 
pressed in four different non-endocrine cell lines [22]. 
Besides, we could, by deleting the C-terminal peptide 
(residues 156170), obtain amidation of the expressed 
VIP. It has been suggested that expression of C-termi- 
48 
nally deleted peptide precursors could be used for the 
expression of small amidated peptides in non-endocrine 
cells [6]. However, this concept could not be directly 
applied to the expression of VIP as the C-terminally 
truncated VIP is only partially processed N-terminal to 
the VIP sequence. Furthermore the length of VIP plus 
the signal peptide is probably less than the required 
length to enter the secretory pathway [19], and conse- 
quently a N-terminal extension of the peptide is required. 
Efficient cleavage at this site was obtained by changing 
the cleavage site N-terminal to VIP into a consensus 
cleavage site for the ubiquitous processing enzyme furin. 
Using this method it will be possible to express small 
modified peptides, e.g. peptides with disulfide bridges, 
amidated peptides and glycosylated peptides (e.g. endo- 
thelin, calcitonin and vasopressin that all contain at least 
one disulfide bridge), in non-endocrine cell lines, which 
are generally used for large-scale production. Possibly 
the processing in these cells can be optimized by engi- 
neering the cell line to over-express furin and car- 
boxypeptidase E. Over-expression of furin in COS-7 cells 
was found to increase the cleavage efficiency in a mu- 
tated proinsulin with a tetrabasic cleavage site [23]. An- 
other possibility is to screen a number of non-endocrine 
cell lines for the expression of furin, carboxypeptidase H
and amidating enzyme, and choose a cell line with a 
suitable enzyme combination. 
Media from cells expressing [PV121,122RR,~l156 
170lpreproVIP and from cells expressing preproVIP 
were able to activate the VIP receptor as demonstrated 
by induction of CAMP production in CHO cells express- 
ing the VIP receptor. The highest amounts of CAMP was 
produced after addition of 50 ~1 media from cells ex- 
pressing [PVl21,122RR,d15617O]preproVIP (36 pmol/ 
10’ cells). However, media from the cells expressing the 
wild-type precursor also significantly increased the 
CAMP production, (50 ~1 media from preproVIP ex- 
pressing cells produced 23 pmol CAMP/IO’ cells). This 
indicates that VIP extended C-terminally by residues 
15&170 is able to bind to and activate the receptor. 
Although this extended VIP form is not found in tissue, 
the observation corresponds to the finding that both 
PHM and its C-terminally extended form, PHV has bio- 
logical activity [ 131 and to the finding that both PACAP 
27 and PACAP 38 are biologically active [24]. 
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